Anixa Biosciences
ANIX
45 hedge funds and large institutions have $11.7M invested in Anixa Biosciences in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 5 closing their positions.
531% more call options, than puts
Call options by funds: $164K | Put options by funds: $26K
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 44 → 45 (+1)
0.07% less ownership
Funds ownership: 11.85% → 11.77% (-0.07%)
26% less capital invested
Capital invested by funds: $15.8M → $11.7M (-$4.08M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$146K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$121K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$111K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84.6K |
| 5 |
JP Morgan Chase
New York
|
+$83.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$418K |
| 2 |
Jane Street
New York
|
-$266K |
| 3 |
VF
Virtu Financial
New York
|
-$79K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$65.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$65.3K |
ANIX Hedge Fund Activity: Q2 2023 in Review
45 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q2 2023, worth a combined $11.7M — down 26% from $15.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ANIX positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 8 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $146K. The largest seller was Susquehanna International Group, cutting an estimated $418K.
- 45 institutional investors held Anixa Biosciences (ANIX) as of Q2 2023, up from 44 in Q1 2023.
- Funds reported $11.7M of Anixa Biosciences stock for Q2 2023, down 26% quarter-over-quarter.
- 6 funds opened new Anixa Biosciences positions in Q2 2023 and 5 closed out, a net change of +1 holder.
- The largest Anixa Biosciences buyer in Q2 2023 was Renaissance Technologies, an estimated $146K added.
- The largest Anixa Biosciences seller in Q2 2023 was Susquehanna International Group, an estimated $418K sold.
Based on aggregated 13F filings for Q2 2023.